GlassScriptPhysician profile
Lamis Kobeissi
NPI 1578716668
$4,224.94
in general payments reported to CMS, 2019-2025
29 companies · $746 in 2025
The $746 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $915 · 2023: $972 · 2024: $968 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $743.24 | 2022-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $695.92 | 2021-2024 | Jornay Pm |
| Tris Pharma INC | $657.13 | 2021-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $211.89 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $197.06 | 2025 | Jornay Pm |
| Kaleo, INC. | $170.87 | 2021-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $164.94 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $158.33 | 2021-2025 | |
| Alk-Abello, INC | $155.57 | 2023-2024 | Grastek, Odactra, Ragwitek |
| Cranial Technologies, INC | $141.40 | 2022-2025 | Doc Band |
| Pfizer INC. | $116.80 | 2021-2023 | |
| Neurelis, INC. | $112.61 | 2022-2023 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $78.57 | 2021-2024 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $73.94 | 2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $61.94 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $58.21 | 2025 | Zelsuvmi |
| Adlon Therapeutics L.P. | $54.89 | 2021 | |
| Aytu Biopharma, INC. | $52.26 | 2024-2025 | Karbinal |
| Seqirus USA INC | $49.29 | 2022-2025 | Flucelvax |
| Noven Therapeutics, LLC | $37.74 | 2025 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $37.31 | 2024-2025 | Relexxii |
| Acadia Pharmaceuticals INC | $30.90 | 2025 | Daybue |
| Cvrx, INC. | $30.38 | 2023 | Barostim Neo System |
| Aimmune Therapeutics, INC. | $29.30 | 2022 | |
| Biomarin Pharmaceutical INC. | $28.31 | 2024 | Voxzogo 1.2mg |
| Bayer Healthcare Pharmaceuticals INC. | $26.76 | 2024 | |
| Chiesi USA, INC. | $20.05 | 2024 | Filsuvez |
| Teva Pharmaceuticals USA, INC. | $15.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamis Kobeissi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.